Ebenbuild
Ebenbuild is a deep tech health tech company based in Munich, Germany, specializing in personalized health intelligence for lung diseases through advanced computational models. Their core technology is a digital twin platform that creates personalized, predictive lung simulations based on physics, physiology, and biochemistry to improve healthcare outcomes. Ebenbuild's platform serves both clinical and industrial users by enabling precise decision-making in hospitals for treatment optimization and supporting drug development with in silico trials that predict drug delivery success to the lungs. The company focuses on maximizing patient benefit by bridging healthcare and life sciences, with applications in clinical decision support and in silico trials. Ebenbuild has gained traction through collaborations with hospitals and research institutions, participation in regulatory discussions, and recognition in biotech and AI startup landscapes. Their business model is primarily SaaS and subscription-based, targeting healthcare providers, biotech, pharma, and medtech companies. The team includes founders and experts in biomedical engineering, AI, and software development, with notable advisors from the medical technology field.
Ebenbuild
Ebenbuild is a deep tech health tech company based in Munich, Germany, specializing in personalized health intelligence for lung diseases through advanced computational models. Their core technology is a digital twin platform that creates personalized, predictive lung simulations based on physics, physiology, and biochemistry to improve healthcare outcomes. Ebenbuild's platform serves both clinical and industrial users by enabling precise decision-making in hospitals for treatment optimization and supporting drug development with in silico trials that predict drug delivery success to the lungs. The company focuses on maximizing patient benefit by bridging healthcare and life sciences, with applications in clinical decision support and in silico trials. Ebenbuild has gained traction through collaborations with hospitals and research institutions, participation in regulatory discussions, and recognition in biotech and AI startup landscapes. Their business model is primarily SaaS and subscription-based, targeting healthcare providers, biotech, pharma, and medtech companies. The team includes founders and experts in biomedical engineering, AI, and software development, with notable advisors from the medical technology field.